Diagnostic Performance of Metagenomic Next-Generation Sequencing in Central Nervous System Cryptococcosis Using Cerebrospinal Fluid

被引:4
|
作者
Zhang, Xuan [1 ]
Lin, Yaqing [2 ]
Chen, Huixin [1 ]
Hu, Jianhua [1 ]
Zhao, Hong [1 ]
Yang, Meifang [1 ]
Han, Dongsheng [3 ,4 ,5 ]
机构
[1] Zhejiang Univ, Sch Med,Affiliated Hosp 1,Natl Clin Res Ctr Infec, Collaborat Innovat Ctr Diag & Treatment Infect Di, Natl Med Ctr Infect Dis,State Key Lab Diag & Trea, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Shuren Univ, Shulan Hangzhou Hosp, Shulan Int Med Coll, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Lab Med, Hangzhou, Zhejiang, Peoples R China
[4] Key Lab Clin Vitro Diagnost Techn Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China
[5] Zhejiang Univ, Inst Lab Med, Hangzhou, Zhejiang, Peoples R China
来源
关键词
metagenomic next-generation sequencing; central nervous system cryptococcosis; cerebrospinal fluid; invasive fungal infection; MENINGITIS;
D O I
10.2147/IDR.S425463
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose: Metagenomic next-generation sequencing (mNGS) has been widely used to diagnose infectious diseases. However, there are few studies on its diagnostic performance in the central nervous system (CNS) cryptococcosis. This study examined the diagnostic efficacy of mNGS in identifying Cryptococcus spp. in cerebrospinal fluid (CSF) samples.Patients and Methods: From March 2021 to March 2023, 290 patients with suspected CNS infection were recruited from the First Affiliated Hospital, School of Medicine, Zhejiang University, and 74 patients were ultimately included in the study. Lastly, 22 patients with CNS cryptococcosis were included. Of these patients, 25 CSF samples were enrolled. The diagnostic performance of conventional assays [including India ink, cryptococcal antigen (CrAg) testing, and culture] and mNGS was evaluated for CNS cryptococcosis.Results: In the 25 samples collected, the coincidence rates of mNGS with India ink, CrAg, and culture were 64.0% (16/25), 80.0% (20/25), and 80.0% (20/25), respectively. Without antifungal drug exposure, the coincidence rates were increased to 66.7% (10/15), 100.0% (15/15), and 93.3% (14/15), respectively. The coincidence rates after antifungal therapy were all decreased to 60.0% (6/10), 50.0% (5/10), and 60.0% (6/10), respectively. Moreover, in the 25 samples, the sensitivity of mNGS reached 80.0%, and of India ink, CrAg testing, and culture were 68.0, 100.0, and 60.0%, respectively. The mNGS showed an excellent positive rate (100.0%) in the 15 samples collected without antifungal drug exposure, which was significantly higher than the antifungal drug-exposed group (n = 10) (50.0%) (P = 0.005). The reads of Cryptococcus spp. before antifungal therapy were significantly higher than after it (median, 25,915 vs 2, P = 0.008).Conclusion: mNGS is an effective tool for diagnosing CNS cryptococcosis using CSF; however, its sensitivity decreases considerably in patients who have been effectively treated with antifungal drugs.
引用
收藏
页码:6175 / 6183
页数:9
相关论文
共 50 条
  • [21] Use of Metagenomic Next-Generation Sequencing to Identify Pathogens Involved in Central Nervous System Infections
    Zhan, Liying
    Lv, Zhihua
    Zhang, Yunjing
    Chen, Jingdi
    Wang, Lu
    Huang, Raojuan
    Sun, Yaqi
    Wu, Wei
    INFECTION AND DRUG RESISTANCE, 2024, 17
  • [22] The clinical utility of metagenomic next-generation sequencing for the diagnosis of central nervous system infectious diseases
    Pan, Xiaoying
    Zhang, Yuefeng
    Chen, Guohua
    NEUROLOGICAL RESEARCH, 2023, 45 (10) : 919 - 925
  • [23] Clinical application value of metagenomic next-generation sequencing in the diagnosis of central nervous system infections
    Liu, Ying
    Zhu, Weiwei
    Jiao, Mengfan
    Guo, Wenhu
    Luo, Yonggang
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2023, 11
  • [24] Metagenomic Next-Generation Sequencing Contributes to the Early Diagnosis of Mixed Infections in Central Nervous System
    Lin, Li
    Fang, Junyue
    Li, Jiahao
    Tang, Ying
    Xin, Tengteng
    Ouyang, Nengtai
    Cai, Wenying
    Xie, Lisi
    Lu, Sha
    Zhang, Junmin
    MYCOPATHOLOGIA, 2024, 189 (03)
  • [25] The clinical utility of metagenomic next-generation sequencing for the diagnosis of central nervous system infectious diseases
    Pan, Xiaoying
    Zhang, Yuefeng
    Chen, Guohua
    NEUROLOGICAL RESEARCH, 2023,
  • [26] Understanding etiology of community-acquired central nervous system infections using metagenomic next-generation sequencing
    Zhang, Shanshan
    Wu, Gang
    Shi, Yuru
    Liu, Ting
    Xu, Liangfei
    Dai, Yuanyuan
    Chang, Wenjiao
    Ma, Xiaoling
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2022, 12
  • [27] Diagnostic performance of metagenomic next-generation sequencing for Pneumocystis jirovecii pneumonia
    Xuefang Li
    Zhijun Li
    Jian Ye
    Wu Ye
    BMC Infectious Diseases, 23
  • [28] The microbiological diagnostic performance of metagenomic next-generation sequencing in patients with sepsis
    Di Ren
    Chao Ren
    Renqi Yao
    Lin Zhang
    Xiaomin Liang
    Guiyun Li
    Jiaze Wang
    Xinke Meng
    Jia Liu
    Yu Ye
    Haoli Li
    Sha Wen
    Yanhong Chen
    Dan Zhou
    Xisi He
    Xiaohong Li
    Kai Lai
    Ying Li
    Shuiqing Gui
    BMC Infectious Diseases, 21
  • [29] Diagnostic performance of metagenomic next-generation sequencing for Pneumocystis jirovecii pneumonia
    Li, Xuefang
    Li, Zhijun
    Ye, Jian
    Ye, Wu
    BMC INFECTIOUS DISEASES, 2023, 23 (01)
  • [30] The microbiological diagnostic performance of metagenomic next-generation sequencing in patients with sepsis
    Ren, Di
    Ren, Chao
    Yao, Renqi
    Zhang, Lin
    Liang, Xiaomin
    Li, Guiyun
    Wang, Jiaze
    Meng, Xinke
    Liu, Jia
    Ye, Yu
    Li, Haoli
    Wen, Sha
    Chen, Yanhong
    Zhou, Dan
    He, Xisi
    Li, Xiaohong
    Lai, Kai
    Li, Ying
    Gui, Shuiqing
    BMC INFECTIOUS DISEASES, 2021, 21 (01)